Systemic sclerosis & Raynaud's
Dual positivity for Anti-Ro52 and Anti-Ro60 antibodies is linked to greater organ involvement and disease progression in systemic sclerosis
Authors' conclusion
Dual positivity for anti-Ro52 and anti-Ro60 antibodies identifies a distinct SSc subgroup with severe organ involvement and accelerated disease progression, particularly ILD.
Study context
- Population
- Systemic sclerosis (SSc) patients with at least 1 year of follow-up, Renji Scleroderma Longitudinal Cohort
- Participants
- 379 patients
- Exposure
- Ro52+/Ro60+ double-positive vs other serological groups
- Ro52+/Ro60+n = 48
- Outcome
- Clinical features (organ involvement) and disease progression
Methodological detailssingle-centre, observational, longitudinal cohort (Renji Scleroderma Longitudinal Cohort (Renji-SLOC)), multivariable logistic regression, survival analysis
- Single-centre
- Observational
- Longitudinal cohort (Renji-SLOC)
- Multivariable logistic regression
- Survival analysis
Main finding
As reported in the abstract
Organ involvement (multivariable analysis)
Double-positive: ILD
79.2%
Double-positive: PAH
25.0%
Double-positive: digital ulcers
41.7%
Double-positive: gastrointestinal symptoms
79.2%
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Dual positivity for Anti-Ro52 and Anti-Ro60 antibodies is linked to greater organ involvement and disease progression in systemic sclerosis. Semin Arthritis Rheum. Published 12 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →